Cardiac dysfunction in adipose triglyceride lipase deficiency: treatment with a PPARα agonist

The peroxisome proliferator-activated receptor-α (PPAR-α) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats

(2009) Wolfgang Linz et al.   ACTA PHARMACOLOGICA SINICA

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

(2009) Philip D Home et al.   LANCET

Chronic treatment with the peroxisome proliferator-activated receptor α agonist Wy-14,643 attenuates myocardial respiratory capacity and contractile function

(2009) Makhosazane Zungu et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease

(2009) Emma Robinson et al.   PHARMACOLOGY & THERAPEUTICS

Novel mutations in the adipose triglyceride lipase gene causing neutral lipid storage disease with myopathy

(2008) Filomena Campagna et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Diabetes-related metabolic perturbations in cardiac myocyte

(2008) D. Feuvray et al.   DIABETES & METABOLISM

Differential transcriptional modulation of biological processes in adipocyte triglyceride lipase and hormone-sensitive lipase-deficient mice

(2008) Montserrat Pinent et al.   GENOMICS

Triglyceride Deposit Cardiomyovasculopathy

(2008) Ken-ichi Hirano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Peroxisome Proliferator-Activated Receptor α Agonists Enhance Cardiomyogenesis of Mouse ES Cells by Utilization of a Reactive Oxygen Species-Dependent Mechanism

(2007) Fatemeh Sharifpanah et al.   STEM CELLS